Bradykinin and Cancer

Handbook of Biologically Active Peptides

Volumn , Issue , 2006, Pages 443-446

  Stewart, John M ^a   Gera, Lajos ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052709408     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369442-3/50066-0     Document Type: Chapter

References (25)

1. Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, et al. A novel class of orally active non-peptide bradykinin B2 antagonists. J Med Chem 1998, 41:4053-4061.
2. Austin CE, Foreman JC, Scadding GK Reduction by HOE-140, the B-2 kinin receptor antagonist, of antigen-induced nasal blockage. Br J Pharmacol 1994, 111:969-971.
3. Barki-Harrington L, Daaka Y Kinin-regulated growth of androgen-insensitive prostate cancer PC3 cells requires direct interaction between bradykinin 1 and bradykinin 2 receptors. J Urol 2001, 165:2121-2125.
4. Bhoola KD, Figueroa CD, Worthy K Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992, 44:1-80.
5. Bunn PA, Chan DC, Dienhart DG, Tolly R, Togawa M, Jewett PB Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res 1991, 52:24-31.
6. Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, et al. Bradykinin antagonist dimer CU-201 inhibits the growth of human lung cancer cells by a novel "biased agonist" mechanism. Proc Natl Acad Sci USA 2002, 99:4608-4613.
7. Chan D, Gera L, Stewart J, Helfrich B, Zhao TL, Feng WY, et al. Bradykinin antagonist dimer CU-201 inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res 2002, 8:1280-1287.
8. Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Ko SY, Wrigglesworth R, et al. 1-(2-nitrophenyl) thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B2 receptor. J Med Chem 2000, 43:769-771.
9. Larrivee JF, Gera L, Houle S, Bouthillier J, Bachvarov DR, Stewart JM, et al. Non-competitive pharmacological antagonism at the rabbit B1 receptor. Brit J Pharmacol 2000, 131:885-892.
10. Lembeck F, Griesbacher T, Eckhardt M, Menke S, Breipohl G, Knolle J New, long-acting, potent bradykinin antagonists. Br J Pharmacol 1991, 102:297-304.
11. Marceau F, Hess JF, Bachvarov DR The B1 receptors for kinins. Pharmacol Rev 1998, 50:357-386.
12. Marceau F. Personal communication.
13. Pruneau D, Paquet JL, Luccarini JM, Defrêne E, Fouchet C, Franck, et al. Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin antagonist. Immunopharmacol 1999, 43:187-194.
14. Regoli D, Barabe J, Park WK Receptors for bradykinin in rabbit aorta. Can J Physiol Pharmacol 1977, 55:855-867.
15. Ritchie TJ, Dzaidulewicz EK, Culshaw AJ, Muller W, Burgess GM, Bloomfield GC, et al. Potent and orally bioavailable nonpeptide antagonists at the human bradykinin B1 receptor. J Med Chem 2004, 47:4642-4644.
16. Gougat J, Ferrari BSL, Planchenault C, Poncelet M, Mauani J, Alonso R, et al. J Pharmacol Exp Therap 2004, 309:661-669.
17. Salvino JM, Seoane PR, Douty BD, Awad MMA, Dolle RE, Houck WT, et al. Design of potent, non-peptide antagonists of the human bradykinin B2 receptor. J Med Chem 1993, 36:2583-2584.
18. Stewart JM Bradykinin antagonists as anti-cancer agents. Curr Pharmaceut Design 2003, 9:2036-2042.
19. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, Zuzack JS Potent, long-acting, orally active bradykinin antagonists for a wide variety of applications. Immunopharmacol 1997, 36:167-172.
20. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA, et al. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides 2005, 26:1288-1291.
21. Stewart JM, Gera L, Hanson W, Zuzack JS, Burkard M, McCullough R, et al. A new generation of bradykinin antagonists. Immunopharmacol 1996, 33:51-60.
22. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, et al. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 2005, 26:1292-1300.
23. Vavrek RJ, Stewart JM Competitive antagonists of bradykinin. Peptides 1985, 6:161-164.
24. Witherow FN, Helmy A, Webb DJ, Fox KAA, Newby DE Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failture. Circulation 2001, 104:2177-2181.
25. Woll PJ, Rozengurt E Multiple neuropeptides mobilize calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. Biochem Biophys Res Commun 1989, 164:66-73.